Drug Profile

Muscarinic M4 receptor agonist - Cerevel Therapeutics

Alternative Names: M4 agonist - Cerevel Therapeutics

Latest Information Update: 05 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

01 Aug 2024 Cerevel Therapeutics has been acquired by AbbVie
28 May 2024 No recent reports of development identified for preclinical development in Drug-induced-dyskinesia in USA
31 Dec 2023 Cerevel Therapeutics has patents protection for muscarinic M4 receptor agonist in the US and in foreign jurisdictions prior to December 2023

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com